You are here

Bayer To Take Birth Control Device Essure Off the U.S. Market

Some studies had linked the device to harmful side effects.

The birth control device Essure is taking its final bow. The United States was the last market in which Essure, manufactured by Bayer AG, had been sold. As the Wall Street Journal reports, the company decided to stop selling the product because of declining sales. “The U.S. is the only remaining market where the German pharmaceutical and chemicals company sells Essure,” the newspaper reports. “The company said in a statement it sold Essure in a total of 21 countries, but ended sales of the implant in all countries but the U.S. last year on a ‘lack of interest in the product.’”

The device has been associated with some controversy. The FDA in 2016 told Bayer that it must add a warning saying that some studies have linked Essure to pain and “other health issues among women.”

Bayer has cited “inaccurate” publicity about the product as one of the reasons for declining sales. The company said in a statement: “Our decision to discontinue sales is for business reasons, and not for any safety or efficacy concerns about Essure.”

More Headlines

BTC Is a Group of Rare Gastrointestinal Cancers With Limited Treatment Options, Poor Outcomes
Study Demonstrates Rapid Response in Patients, and Doesn’t Affect Tamoxifen Efficacy
Prescription App Can Serve As Training, Monitoring, and Reminder Tool
Resorbable Dextenza is the First Intracanalicular Insert for Drug Delivery
Patients with MS Suffered Stroke, Blood Vessel Tearing in Head and Neck After Receiving Drug
First Biosimilar For Adults With CD20-Positive, B-Cell Non-Hodgkin’s Lymphoma
Life-Threatening Side Effect of Drug for Acute Myeloid Leukemia
First Drug for Rare Autoimmune Disorder That Affects Nerve, Muscles Connection